Every material Form 8-K Innoviva filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Innoviva reported third-quarter 2025 total revenue of $107.8 million, up 20% from a year earlier, and net income of $89.9 million, or $1.30 basic per share, compared with $1.2 million in the prior-year quarter. Income from operations fell 20% to $34.6 million, which the company attributed mainly to a non-recurring research and development expense, while net favorable changes in investment fair values drove the higher net income. The company also announced a new share repurchase program of up to $125 million.
Total revenue was $107.8 million, up 20% from $89.5 million in Q3 2024.
Net income was $89.9 million, or $1.30 basic per share, versus $1.2 million, or $0.02 per share, a year earlier.
Income from operations was $34.6 million, down 20% from $43.2 million, mainly due to a non-recurring R&D expense.
Board authorized a new share repurchase program of up to $125.0 million, with no termination date.
Innoviva reported second quarter 2025 results on August 6, 2025. Total revenue was $100.3 million, up slightly from $99.9 million a year earlier, and the company swung to net income of $63.7 million, or $1.01 basic per share, from a net loss of $34.7 million. Income from operations fell 11% to $48.8 million, while favorable changes in investment fair values helped the bottom line.
Total revenue of $100.3 million, compared with $99.9 million in Q2 2024
Net income of $63.7 million, or $1.01 basic per share, versus a net loss of $34.7 million, or $(0.55) per share, a year earlier
Income from operations of $48.8 million, down 11% from $54.7 million, partly due to zoliflodacin R&D costs
U.S. net product sales of $29.0 million, up 54% from $18.8 million; zoliflodacin PDUFA date is December 15, 2025
Innoviva reported first-quarter 2025 total revenue of $88.6 million, up from $77.5 million a year earlier, and income from operations rose 61% to $41.4 million. Unfavorable fair value changes in equity and long-term investments of $78.8 million produced a net loss of $46.6 million, or $0.74 per basic share, compared with net income of $36.5 million, or $0.58 per share, in the first quarter of 2024. The results are mixed for shareholders: operating performance improved, but investment valuation losses turned the bottom line negative.
Total revenue was $88.6 million versus $77.5 million; income from operations was $41.4 million, up from $25.8 million.
U.S. net product sales were $26.4 million, a 52% increase year over year, led by $17.4 million from GIAPREZA.
Net loss was $46.6 million, or $0.74 per basic share, versus net income of $36.5 million, or $0.58 per share.
Gross royalty revenue from GSK was $61.3 million, compared with $61.9 million; cash and cash equivalents were $319.1 million at March 31, 2025.
Innoviva reported fourth quarter 2024 total revenue of $91.8 million, up from $85.8 million a year earlier, with U.S. net product sales of $24.9 million. Net income fell to $20.3 million, or $0.32 basic earnings per share, from $61.5 million, or $0.97, a year earlier, as the company cited changes in fair values of equity investments. The company said it expects U.S. net product sales to exceed $100 million in 2025.
Q4 2024 total revenue was $91.8 million, compared with $85.8 million in Q4 2023.
Q4 2024 net income was $20.3 million ($0.32 basic EPS), versus $61.5 million ($0.97) in Q4 2023.
Full year 2024 total revenue was $358.7 million and net income was $23.4 million ($0.37 basic EPS).
Company forecasts 2025 U.S. net product sales to exceed $100 million and plans a ZEVTERA launch in mid-2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Innoviva filing is on SEC EDGAR ↗. 8-K briefs of other companies →